DRF 3188 a novel semi-synthetic analog of andrographolide: cellular response to MCF 7 breast cancer cells

Abstract Background We determined the effect of andrographolide and one of its novel semi-synthetic analog, DRF 3188, on the cell cycle of MCF 7 breast cancer cells. Methods The effect of the compounds on cell cycle was determined using FACS and western blot analysis of cell cycle proteins. Hollow fibre assay was used to determine if the compounds had the same effect on the cell cycle in vitro and in vivo. Results Our results from the in vitro and in vivo experiments show that both the compounds block the cell cycle at the G0-G1 phase through the induction of the cell cycle inhibitor, p27, and the concomitant decrease in the levels of Cdk4. Conclusion The results show that the novel semi-synthetic analog, DRF3188, and andrographolide bring about the anti cancer activity by a similar mechanism.</p

Western blot analysis of cells treated with Andrographolide (25 μM) or DRF 3188 (5 μM) for 24 hours

<p><b>Copyright information:</b></p><p>Taken from "DRF 3188 a novel semi-synthetic analog of andrographolide: cellular response to MCF 7 breast cancer cells"</p><p>BMC Cancer 2004;4():26-26.</p><p>Published online 18 Jun 2004</p><p>PMCID:PMC441383.</p><p>Copyright © 2004 Satyanarayana et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</p> An induction of the cell cycle inhibitor p27 and reduction in the levels of Cdk4 is observed. No change is observed in the levels of Cyclin D1, Cdk1 or Cyclin B1 in DRF 3188 treated cells. A similar effect is seen in the andrographolide treated cells, but a slight decrease in the level of Cdk 1 is observed. Lovastatin treated cells show decreased levels of Cdk1 and cyclin B1. Actin is used as the internal loading control. Densitometric analysis of the western blot with p27 antibody. An induction of p27 is seen in MCF7 cells treated with 25 uM Lovastatin (4.5 fold), 25 uM Andrographolide (3 fold) and 5 uM DRF3188 (2 fold). C) Densitometric analysis of the western blot with Cdk4 antibody. A decrease in the levels of Cdk4 is seen when MCF7 cells are treated with 25 uM Lovastatin (0.4 fold), 25 uM Andrographolide (0.8 fold) and 5 uM DRF3188 (0.4 fold)

DRF 3188 a novel semi-synthetic analog of andrographolide: cellular response to MCF 7 breast cancer cells-0

<p><b>Copyright information:</b></p><p>Taken from "DRF 3188 a novel semi-synthetic analog of andrographolide: cellular response to MCF 7 breast cancer cells"</p><p>BMC Cancer 2004;4():26-26.</p><p>Published online 18 Jun 2004</p><p>PMCID:PMC441383.</p><p>Copyright © 2004 Satyanarayana et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</p